» Articles » PMID: 39161767

Exploring the Bone Marrow Micro Environment in Thalassemia Patients: Potential Therapeutic Alternatives

Overview
Journal Front Immunol
Date 2024 Aug 20
PMID 39161767
Authors
Affiliations
Soon will be listed here.
Abstract

Genetic mutations in the β-globin gene lead to a decrease or removal of the β-globin chain, causing the build-up of unstable alpha-hemoglobin. This condition is referred to as beta-thalassemia (BT). The present treatment strategies primarily target the correction of defective erythropoiesis, with a particular emphasis on gene therapy and hematopoietic stem cell transplantation. However, the presence of inefficient erythropoiesis in BT bone marrow (BM) is likely to disturb the previously functioning BM microenvironment. This includes accumulation of various macromolecules, damage to hematopoietic function, destruction of bone cell production and damage to osteoblast(OBs), and so on. In addition, the changes of BT BM microenvironment may have a certain correlation with the occurrence of hematological malignancies. Correction of the microenvironment can be achieved through treatments such as iron chelation, antioxidants, hypoglycemia, and biologics. Hence, This review describes damage in the BT BM microenvironment and some potential remedies.

Citing Articles

Microenvironmental dynamics in steady-state and stress erythropoiesis.

Yang C, Suda T Blood Sci. 2025; 7(1):e00219.

PMID: 39949502 PMC: 11822345. DOI: 10.1097/BS9.0000000000000219.


Neutrophil Diversity (Immature, Aged, and Low-Density Neutrophils) and Functional Plasticity: Possible Impacts of Iron Overload in β-Thalassemia.

Sae-Khow K, Charoensappakit A, Leelahavanichkul A Int J Mol Sci. 2024; 25(19).

PMID: 39408979 PMC: 11476590. DOI: 10.3390/ijms251910651.

References
1.
Steensma D, Gibbons R, Higgs D . Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood. 2004; 105(2):443-52. DOI: 10.1182/blood-2004-07-2792. View

2.
Huang J, Zhao Y, Zhao K, Yin K, Wang S . Function of reactive oxygen species in myeloid-derived suppressor cells. Front Immunol. 2023; 14:1226443. PMC: 10461062. DOI: 10.3389/fimmu.2023.1226443. View

3.
Rostami T, Kasaeian A, Maleki N, Nikbakht M, Kiumarsi A, Tavangar S . The effect of bone marrow-derived mesenchymal stem cell co-transplantation with hematopoietic stem cells on liver fibrosis alleviation and survival in patients with class III β-thalassemia major. Stem Cell Res Ther. 2021; 12(1):213. PMC: 8008651. DOI: 10.1186/s13287-021-02242-8. View

4.
Nyamondo K, Wheadon H . Micro-environment alterations through time leading to myeloid malignancies. Br J Pharmacol. 2022; 181(2):283-294. DOI: 10.1111/bph.15924. View

5.
Honig G, Suarez C, Vida L, Lu S, Liu E . Juvenile myelomonocytic leukemia (JMML) with the hematologic phenotype of severe beta thalassemia. Am J Hematol. 1998; 58(1):67-71. DOI: 10.1002/(sici)1096-8652(199805)58:1<67::aid-ajh12>3.0.co;2-2. View